Physician profile
Debra E Solom
NPI 1003848516
$1,802.39
in general payments reported to CMS, 2019-2025
23 companies · $14.47 in 2025
The $14.47 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $273 · 2023: $1,305 · 2025: $14.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.67 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $307.73 | 2021-2023 | Darzalex, Tecvayli |
| Celgene Corporation | $215.15 | 2022-2023 | Opdualag, Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $162.05 | 2021-2023 | Enhertu |
| Astellas Pharma US INC | $158.53 | 2021-2023 | Padcev |
| Incyte Corporation | $135.10 | 2023 | Monjuvi, Jakafi, Pemazyre |
| Gilead Sciences, INC. | $133.26 | 2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $93.71 | 2022-2023 | Keytruda, Lynparza |
| Kite Pharma, INC. | $75.89 | 2023 | Yescarta |
| Emd Serono, INC. | $62.72 | 2021-2023 | Bavencio |
| Seagen INC. | $62.46 | 2023 | Tukysa |
| Mirati Therapeutics, INC. | $60.82 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $55.84 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $52.61 | 2022-2023 | |
| Stemline Therapeutics INC. | $46.48 | 2023 | Orserdu |
| Beigene USA, INC. | $31.50 | 2022-2023 | Brukinsa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $29.00 | 2023 | Mektovi, Braftovi, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $22.58 | 2023 | Tagrisso |
| Genzyme Corporation | $21.63 | 2023 | |
| Lilly USA, LLC | $19.00 | 2023 | Jaypirca |
| Pharmacosmos Therapeutics INC. | $14.47 | 2025 | Monoferric |
| Genentech USA, INC. | $14.34 | 2021 | |
| Sobi, INC | $14.20 | 2022 | |
| Taiho Oncology, INC. | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Solom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.